• Technology
  • Applications
    • AML MRD
    • Mutagenesis
    • Cellular Immunotherapy
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
  • Contact
TwinStrand Biosciences
  • Technology
  • Applications
    • AML MRD
    • Mutagenesis
    • Cellular Immunotherapy
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
  • Contact
Chimerism detection at one-in-one-million sensitivity Learn More

Mutation frequency, spectra, and signatures directly from DNA
Learn More
 

Identify AML-related mutations with 100-fold higher resolution Learn More

Highest Resolution Next-Generation Sequencing (NGS)

TwinStrand Duplex Sequencing™ technology reduces your sequencing error rates from 1-in-100 to 1-in-10 million, revealing data otherwise hidden. Using a combination of proprietary biochemistry and cloud-based informatics, the limitations of standard sequencing are overcome by independently tracking both strands of individual DNA molecules and comparing the results to eliminate errors.

 

SEE HOW

Detect Rare Variants Like Never Before

Whether you are studying measurable residual disease, mutation signatures, cellular immunotherapy monitoring, or any low-level variants, you need accuracy beyond standard NGS. TwinStrand Duplex Sequencing reveals important low frequency variants that aren’t detectable by other methods. Get started with an off-the-shelf kit, or collaborate with us on a custom kit for your specific needs.

 

LEARN MORE

News


TwinStrand Biosciences Explores Error Reduction Sequencing Tech in Various Applications – January 6, 2021

 

 

SEE ALL NEWS

Virtual Events


AGBT21 General Virtual Meeting Bronze Sponsorship Presentation March 1-3, 2021

 

 

SEE ALL EVENTS

Science


Direct Quantification of In Vivo Mutagenesis and Carcinogenesis Using Duplex Sequencing

 

SEE MORE PUBLICATIONS

Customer Quotes

“Mutagenicity testing is a requirement for all pharmaceuticals and chemicals used in commerce. The conventional tests used today to identify whether chemicals and drugs cause mutations are decades old and generally investigate a single gene at a time in select organisms. We believe that TwinStrand Duplex Sequencing can revolutionize mutagenicity testing by enabling the precise quantification and characterization of mutations in any gene in any organism. Our initial work, in partnership with Dr. Francesco Marchetti at Health Canada, is establishing experimental designs and analytical approaches for mutagenicity testing in human cells and rodent models.”

 

Carole Yauk
Professor, University of Ottawa
President of the Environmental Mutagenesis and Genomics Society

“My lab’s interactions with TwinStrand have been as much a scientific collaboration as a business relationship. We have worked closely with TwinStrand researchers to develop new panels for mutation detection, and to best leverage Duplex Sequencing and associated bioinformatic pipelines for our studies of cancer evolution in human tissues. These interactions have taken our research in new directions!”

 

James DeGregori
Courtenay C. and Lucy Patten Davis Endowed Chair in Lung Cancer Research
Department of Biochemistry and Molecular Genetics,
University of Colorado Anschutz Medical Campus School of Medicine

Put Duplex Sequencing to work for you.

To get started, click “contact us” below to tell us about your current work and to learn how our Duplex Sequencing technology will revolutionize your research.

 

CONTACT US

 

 

 

TwinStrand Biosciences, Inc.
3131 Elliott Ave, Suite 750 • Seattle, WA 98121 • USA
+1 (877) 202-TWIN

 

For Research Use Only. Not for use in diagnostic procedures.

©2021 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners.  Legal Notices

  

This website uses cookies to improve your experience. Read More. You can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

American Society of Hematology (ASH)

December 5-8, 2020 – Virtual

 

Poster Presentation

 

“Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia”

 

Presented by Jake Higgins, Senior Scientist – December 6, 2020 7:00 a.m.-3:30 p.m. PST

 

Conference Website

 

Society of Toxicology (SOT)

March 10-14, 2019 – Baltimore, MD

 

Poster Presentations

 

 

View Poster

 

 

Conference Website

 

AACR Annual Meeting – San Diego, CA

March 29-April 3, 2019

 

Poster Presentations

 

 

View Poster

 

 

View Poster

Presentations by CEO Jesse Salk, MD, PhD – AGBT 2020

Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Dupex Sequencing